Last Updated: August 9, 2026

Details for Patent: 10,159,645


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,159,645 protect, and when does it expire?

Patent 10,159,645 protects TRIMBOW and is included in one NDA.

This patent has fifty-eight patent family members in forty countries.

Summary for Patent: 10,159,645
Title:Combination therapy for COPD
Abstract:Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.
Inventor(s):Sauro BONELLI, Francesca Usberti, Enrico Zambelli
Assignee: Chiesi Farmaceutici SpA
Application Number:US14/812,190
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery; Device;
Patent landscape, scope, and claims:

error: insufficient information

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,159,645

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Chiesi TRIMBOW beclomethasone dipropionate; formoterol fumarate; glycopyrrolate AEROSOL, METERED;INHALATION 219622-001 May 14, 2026 RX Yes Yes 10,159,645 ⤷  Start Trial Y MAINTENANCE TREATMENT OF ASTHMA ⤷  Start Trial
Chiesi TRIMBOW beclomethasone dipropionate; formoterol fumarate; glycopyrrolate AEROSOL, METERED;INHALATION 219622-002 May 14, 2026 RX Yes Yes 10,159,645 ⤷  Start Trial Y MAINTENANCE TREATMENT OF ASTHMA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,159,645

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2515855 ⤷  Start Trial 300923 Netherlands ⤷  Start Trial
European Patent Office 2515855 ⤷  Start Trial PA2018001 Lithuania ⤷  Start Trial
European Patent Office 2515855 ⤷  Start Trial 122018000007 Germany ⤷  Start Trial
European Patent Office 2515855 ⤷  Start Trial CA 2018 00002 Denmark ⤷  Start Trial
European Patent Office 2515855 ⤷  Start Trial 3/2018 Austria ⤷  Start Trial
European Patent Office 2515855 ⤷  Start Trial LUC00060 Luxembourg ⤷  Start Trial
European Patent Office 2515855 ⤷  Start Trial 1890005-0 Sweden ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.